Core Viewpoint - Silver诺医药-B (02591) has seen its stock price increase by over 5%, marking three consecutive days of gains, currently trading at 43.42 HKD with a transaction volume of 7.6433 million HKD [1] Group 1: Stock Performance - The stock price of Silver诺医药-B has risen by 5.03% [1] - The current trading price is 43.42 HKD [1] - The transaction volume reached 764.33 million HKD [1] Group 2: Market Inclusion - Silver诺医药 has been included in the Hang Seng Composite Index as part of the quarterly review results [1] - The change will take effect on December 8, 2025 [1] Group 3: Company Overview - Silver诺医药 is focused on the field of metabolic diseases [1] - The company has multiple innovative drug development pipelines targeting diabetes, obesity, and non-alcoholic fatty liver disease [1] - All drugs are self-developed and possess global intellectual property rights, with a comprehensive global research and market layout [1]

Core Viewpoint - Silver诺医药-B (02591) has seen a stock price increase of over 5%, marking three consecutive days of gains, currently trading at 43.42 HKD with a transaction volume of 7.6433 million HKD [1] Group 1: Stock Performance - The stock price of Silver诺医药-B has risen by 5.03% [1] - The current trading price is 43.42 HKD [1] - The trading volume reached 7.6433 million HKD [1] Group 2: Index Inclusion - Silver诺医药 has been included in the Hang Seng Composite Index, with changes effective from December 8, 2025 [1] - This inclusion is part of the quarterly review results of the Hang Seng Index series [1] Group 3: Company Overview - Silver诺医药 is focused on the field of metabolic diseases [1] - The company has multiple innovative drug development pipelines targeting diabetes, obesity, and non-alcoholic fatty liver disease, all of which are self-developed [1] - The company holds global intellectual property rights and has a comprehensive global research and market layout [1]

Group 1 - The core viewpoint of the article highlights that Sino Biopharmaceutical-B (02591) has seen a significant stock price increase of over 50% in four trading days, with a current price of 44.68 HKD and a trading volume of 35.37 million HKD [1] - On November 21, the results of the Hang Seng Index series quarterly review were released, and Sino Biopharmaceutical was included in the Hang Seng Composite Index, with the change effective from December 8, 2025 [1] - According to CICC's forecast, Sino Biopharmaceutical is expected to meet the criteria for inclusion in the Hong Kong Stock Connect [1] Group 2 - Sino Biopharmaceutical is focused on the field of metabolic diseases and has a pipeline of innovative drugs targeting conditions such as diabetes, obesity, and non-alcoholic fatty liver disease, all of which are self-developed and possess global intellectual property rights [1] - The company has a comprehensive global research and market layout [1]